Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01701674 · ClinicalTrials.gov registry record · NA
Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts
A NA study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Completed
- Registry status
- NA
- Development phase
- 13
- Enrollment target
NCT01701674 is a NA study that has completed, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 13 participants.
The verdict
NCT01701674, a NA study, has completed, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 13 participants
- Enrollment target
Study Summary
Purpose of this Pilot Study: The investigators want to study the safety, side effects, and benefits of tumor infiltrating lymphocytes (TILs), when they are given with the drug ipilimumab. Ipilimumab is a type of immunotherapy - a drug that is used to boost the ability of the immune system to fight cancer, infection, and other diseases.
Interventions
- DRUG Ipilimumab
- DRUG Administration of Lymphodepletion
- PROCEDURE Tumor Infiltrating Lymphocytes (TIL)
- DRUG Cyclophosphamide as Part of Lymphodepletion
- DRUG Fludarabine as Part of Lymphodepletion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2012-10-09 |
| Est. Completion | 2025-08-21 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01701674
The ClinicalTrials.gov registry entry for NCT01701674 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Ipilimumab is the first listed.
NCT01701674 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01701674 about?
NCT01701674 is a clinical study titled "Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts". Purpose of this Pilot Study: The investigators want to study the safety, side effects, and benefits of tumor infiltrating lymphocytes (TILs), when they are given with the drug ipilimumab. Ipilimumab is a type of immunotherapy - a drug that is used to boost the ability of the immune system to fight c...
What is the current status of trial NCT01701674?
This trial is currently completed. It is a NA study. The enrollment target is 13 participants. The study started on 2012-10-09. Estimated completion is 2025-08-21.
What interventions are being tested in trial NCT01701674?
The interventions under investigation include: Ipilimumab (DRUG), Administration of Lymphodepletion (DRUG), Tumor Infiltrating Lymphocytes (TIL) (PROCEDURE), Cyclophosphamide as Part of Lymphodepletion (DRUG), Fludarabine as Part of Lymphodepletion (DRUG).
Who is sponsoring clinical trial NCT01701674?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.